Sichuan Baili Pharmaceutical Co.Ltd.
Chemotherapy of Physician's Choice(Sichuan Baili Pharmaceutical Co., Ltd.)은 HER2 표적 치료제로, HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis 영역에서 개발·상용화 중입니다. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 32.9% (ClinicalTrials.gov NCT02675231). 차별점: Novel agents and chimeric antigen receptor (CAR)-T cell therapies saw increased use in later lines.
HER2
HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis
Recruiting
ADCs) have transformed solid-tumor therapy and are increasingly
exposure
Novel agents and chimeric antigen receptor (CAR)-T cell therapies saw increased use in later lines
cytokine release syndrome (CRS), and risk of severe neurological events), duration of hospitalization, time until tr
payload exposure pathways to renal injury and electrolyte phenotype hypotheses while contextualizing these patterns against can
HER2-positive
resistance to fluoroquinolones exceeding 57% and resistance to third-generation cephalosporins approximately 48%, whereas the most fa
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Sichuan Baili Pharmaceutical Co.Ltd.
Chemotherapy of Physician's Choice(Sichuan Baili Pharmaceutical Co., Ltd.)은 HER2 표적 치료제로, HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis 영역에서 개발·상용화 중입니다. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 32.9% (ClinicalTrials.gov NCT02675231). 차별점: Novel agents and chimeric antigen receptor (CAR)-T cell therapies saw increased use in later lines.
HER2
HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis
Recruiting
ADCs) have transformed solid-tumor therapy and are increasingly
exposure
Novel agents and chimeric antigen receptor (CAR)-T cell therapies saw increased use in later lines
cytokine release syndrome (CRS), and risk of severe neurological events), duration of hospitalization, time until tr
payload exposure pathways to renal injury and electrolyte phenotype hypotheses while contextualizing these patterns against can
HER2-positive
resistance to fluoroquinolones exceeding 57% and resistance to third-generation cephalosporins approximately 48%, whereas the most fa
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.